JOHNSON & Johnson has lost a key court case in New Jersey, USA, opening up the market for its Zytiga prostate cancer drug to generic competition when the patent lapses tomorrow.
J&J wanted to extend the intellectual protection of Zytiga by introducing prednisone to reduce pain and side effects in cancer patients, but the judge ruled that this was not a novel idea.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Oct 18
